Passionate clinical researcher & PhD candidate at the CIMH, Mannheim, Germany. Licensed psychotherapist (CBT)
Lea Mertens
Goodbye lake como and thank you for a wonderful break after an intense few months of data analysis, paper writing and preparing for my final psychotherapy license exam.
Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!
Excited to share our study on the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression (EPISODE) - now published in @jamapsychiatry.com
A negative effect on primary outcome, but evidence for a relevant antidepressant effect of 25 mg psilocybin with psychotherapy in TRD.
Glad to be at #ACNP2024 in Phoenix!
On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“
alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.
Lea Mertens
Lea Mertens
Lea Mertens
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Reframing Psychedelic Regulation: Tools, not Treatments
In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right.
The use of anesthetics as treatment tools in surgery is a useful analogy.
BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Functional unblinding and expectation may confound efficacy signals in #Psilocybin trials for #Depression, making it difficult to isolate therapeutic effects of psychedelic experiences from placebo and expectancy responses.
ja.ma/4sbCm4u
josh hardman
Max Wolff
Max Wolff
JAMA Psychiatry
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...
